PEG-uricase in the management of treatment-resistant gout and hyperuricemia.

@article{Sherman2008PEGuricaseIT,
  title={PEG-uricase in the management of treatment-resistant gout and hyperuricemia.},
  author={M. R. Sherman and M. G. Saifer and F. Perez-Ruiz},
  journal={Advanced drug delivery reviews},
  year={2008},
  volume={60 1},
  pages={
          59-68
        }
}
Hyperuricemia results from an imbalance between the rates of production and excretion of uric acid. Longstanding hyperuricemia can lead to gout, which is characterized by the deposition of monosodium urate monohydrate crystals in the joints and periarticular structures. Because such deposits are resolved very slowly by lowering plasma urate with available drugs or other measures, the symptoms of gout may become chronic. Persistent hyperuricemia may also increase the risk of renal and… Expand
Physiology of Hyperuricemia and Urate-Lowering Treatments
Recent approaches to gout drug discovery: an update
Therapeutic perspectives on uricases for gout.
Evaluation and Treatment of Gout as a Chronic Disease
The modern management of gout.
Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Hyperuricaemia and gout
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 110 REFERENCES
Emerging therapies in the long‐term management of hyperuricaemia and gout
Renal transplant-associated hyperuricemia and gout.
  • D. Clive
  • Medicine
  • Journal of the American Society of Nephrology : JASN
  • 2000
New developments in clinically relevant mechanisms and treatment of hyperuricemia
A role for uric acid in the progression of renal disease.
...
1
2
3
4
5
...